2-甲基-1,2,3,4-四氢异喹啉-6,7-二醇氢溴酸盐 | 57553-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 2-甲基-1,2,3,4-四氢异喹啉-6,7-二醇氢溴酸盐
• 英文名称: 2-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrobromide salt
• 英文别名: 2-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide；2-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrobromide；2-methyl-3,4-dihydro-1H-isoquinoline-6,7-diol;hydrobromide
• CAS: 57553-18-1
• 化学式: BrH*C₁₀H₁₃NO₂
• 分子量: 260.131
• InChiKey: DIOSEYVQKFBXID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  43.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 在 氢溴酸 作用下， 以 水 为溶剂， 反应 3.0h， 以76%的产率得到2-甲基-1,2,3,4-四氢异喹啉-6,7-二醇氢溴酸盐
  参考文献：
  名称：

  作为自由基前体的改性 B-烷基儿茶酚硼烷

  摘要：

  从 B-烷基儿茶酚硼烷生成自由基代表了一种有效的无锡生成烷基自由基的方法。已经开发了该方法的修改版本。简单的儿茶酚被二羟基化的四氢异喹啉取代，它可以通过用酸水溶液简单萃取而从反应产物中分离出来。通过用 BH3 中心点 Me2S 进行硼氢化反应，然后用二羟基四氢异喹啉处理，很容易从烯烃制备改性烷基自由基前体。这种类型的新型烷基硼酸酯是各种反应中的合适自由基前体，例如苯磺酰化、烯丙基化、炔基化、乙烯基化和醌加成。当从儿茶酚残基中分离反应产物存在问题时，此策略特别有用，

  DOI：

  10.1002/ejoc.201001120

文献信息

• Cephem Compounds with Latent Reactive Groups
  申请人：Gladius Pharmaceuticals, Inc.

  公开号：US20190100534A1

  公开（公告）日：2019-04-04

  Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubstituted or substituted catechol. The leaving group can be a positively charge nitrogen leaving group. Cephems include cephalosporins, cephamycins, carbacephems, and oxacephems. Penems include penems, carbapenems and oxapenems. Preferred cephems are cephalosporins. Preferred penems are carbapenems. Compounds exhibit antibiotic activity against Gram-negative bacteria and/or Gram-positive bacteria. Compounds exhibit antibiotic activity against bacteria which exhibit multi-drug resistance. Compounds of the invention exhibit antibiotic activity against bacterial strains which produce extended spectrum beta-lactamases (ESBL), which produce AmpC beta-lactamases or which produce a carbapenemase. Pharmaceutical compositions comprising one or more cephems or penems or methods of treatment of bacterial infections with such compounds and compositions.

  具有在头孢菌素或青霉烷素环中3位处具有苯乙烯亚甲基基团的头孢菌素和青霉烷素化合物，其中正电离子离去基团与离去基团中含有邻二醇或连接到未取代或取代过的邻苯二酚。离去基团可以是正电离子离去基团。头孢菌素包括头孢菌素、头孢菌烷、卡巴头孢菌素和氧头孢菌素。青霉烷素包括青霉烷素、碳青霉烷素和氧青霉烷素。首选头孢菌素是头孢菌素。首选青霉烷素是碳青霉烷素。化合物对革兰氏阴性细菌和/或革兰氏阳性细菌表现出抗生素活性。化合物对表现出多重耐药性的细菌表现出抗生素活性。本发明的化合物表现出抗生素活性，对产生扩展谱β-内酰胺酶（ESBL）、产生AmpCβ-内酰胺酶或产生碳青霉烷酶的细菌菌株表现出抗生素活性。包括一种或多种头孢菌素或青霉烷素的制药组合物或使用这些化合物和组合物治疗细菌感染的方法。
• Design, Synthesis, and Biological Evaluation of Erythrina Alkaloid Analogues as Neuronal Nicotinic Acetylcholine Receptor Antagonists
  作者：François Crestey、Anders A. Jensen、Morten Borch、Jesper Tobias Andreasen、Jacob Andersen、Thomas Balle、Jesper Langgaard Kristensen

  DOI：10.1021/jm4013592

  日期：2013.12.12

  The synthesis of a new series of Erythrina alkaloid analogues and their pharmacological characterization at various nicotine acetylcholine receptor (nAChR) subtypes are described. The compounds were designed to be simplified analogues of aromatic erythrinanes with the aim of obtaining subtype-selective antagonists for the nAChRs and thereby probe the potential of using these natural products as scaffolds

  描述了一系列新的刺桐生物碱类似物的合成及其在各种烟碱乙酰胆碱受体（nAChR）亚型上的药理学表征。这些化合物被设计为芳香族赤藓醚的简化类似物，目的是获得nAChRs的亚型选择性拮抗剂，从而探索使用这些天然产物作为支架进行进一步配体优化的潜力。最有选择性和最有力的nAChR配体来自6,7-二甲氧基-2-甲基-1,2,3,4-四氢异喹啉（3c）系列（也是O的天然产物）-甲基corypalline），显示出对α4β2nAChR的亚微摩尔结合亲和力，其选择性是α4β4，α3β4和α7的300倍以上。此外，这种铅结构（对单胺氧化酶A和B以及5-羟色胺和去甲肾上腺素转运蛋白也具有抑制活性）在小鼠强迫游泳试验中以30 mg / kg的剂量表现出抗抑郁样作用。
• [EN] CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS<br/>[FR] COMPOSÉS DE CÉPHÈME AYANT DES GROUPES RÉACTIFS LATENTS
  申请人：GLADIUS PHARMACEUTICALS CORP

  公开号：WO2019070973A1

  公开（公告）日：2019-04-11

  Cephem and penem compounds having a styrylmethylene moiety at the 3-position in the cephem or penem ring to which a positively charged leaving group is bonded and wherein the leaving group contains a vicinal diol or is bonded to a unsubstituted or substituted catechol. The leaving group can be a positively charge nitrogen leaving group. Cephems include cephalosporins, cephamycins, carbacephems, and oxacephems. Penems include penems, carbapenems and oxapenems. Preferred cephems are cephalosporins. Preferred penems are carbapenems. Compounds exhibit antibiotic activity against Gram-negative bacteria and/or Gram-positive bacteria. Compounds exhibit antibiotic activity against bacteria which exhibit multi-drug resistance. Compounds of the invention exhibit antibiotic activity against bacterial strains which produce extended spectrum beta-lactamases (ESBL), which produce AmpC beta-lactamases or which produce a carbapenemase. Pharmaceutical compositions comprising one or more cephems or penems or methods of treatment of bacterial infections with such compounds and compositions.